1fe3f1cc7b470f969f39741de811245e067ffba3
EZH2.md
| ... | ... | @@ -7,14 +7,15 @@ link-citations: true |
| 7 | 7 | |
| 8 | 8 | ## Overview |
| 9 | 9 | EZH2 encodes a histone methyltransferase that is a component of the polycomb repressive complex 2 (PRC2). |
| 10 | -This gene is recurrently mutated in both FL and DLBCL and has a common mutation hot spot (Y646) that affects the SET domain.[@morinSomaticMutationsAltering2010a] |
|
| 10 | +This gene is recurrently mutated in both FL and DLBCL and has a common mutation hot spot (Y646) that affects the SET domain.[@morinSomaticMutationsAltering2010a] |
|
| 11 | +EZH2 mutations are one of the defining features of the EZB genetic subgroup of DLBCL.[@wrightProbabilisticClassificationTool2020] |
|
| 12 | +Although mutations in EZH2 have been described in some BL patients, they are extremely rare in most BL cohorts that have been sequenced.[@loveGeneticLandscapeMutations2012; @thomasGeneticSubgroupsInform2023] |
|
| 13 | + |
|
| 11 | 14 | |
| 12 | 15 | ## Experimental Evidence |
| 13 | 16 | |
| 14 | 17 | Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011b] |
| 15 | 18 | Pharmacologic inhibitors of this activity such as tazemetostat have shown benefit in FL.[@morinTreatingLymphomaNow2021] |
| 16 | -EZH2 mutations are one of the defining features of the EZB genetic subgroup of DLBCL.[@wrightProbabilisticClassificationTool2020] |
|
| 17 | -Although mutations in EZH2 have been described in some BL patients, they are extremely rare in most BL cohorts that have been sequenced.[@loveGeneticLandscapeMutations2012; @thomasGeneticSubgroupsInform2023] |
|
| 18 | 19 | |
| 19 | 20 | ## History |
| 20 | 21 | ```mermaid |